Abstract
The major spliceosome comprises the five snRNAs U1, U2, U4, U5 and U6. We recently showed that mutations in RNU4-2, which encodes U4 snRNA, cause one of the most prevalent monogenic neurodevelopmental disorders. Here, we report that recurrent germline mutations in RNU2-2P, a 191bp gene encoding U2 snRNA, are responsible for a related disorder. By genetic association, we implicated recurrent de novo single nucleotide mutations at nucleotide positions 4 and 35 of RNU2-2P among nine cases. We replicated this finding in six additional cases, bringing the total to 15. The disorder is characterized by intellectual disability, neurodevelopmental delay, autistic behavior, microcephaly, hypotonia, epilepsy and hyperventilation. All cases display a severe and complex seizure phenotype. Our findings cement the role of major spliceosomal snRNAs in the etiologies of neurodevelopmental disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was made possible through access to data in the NGRL, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The NGRL holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The NGRL is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centers, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. K.F. was supported by Katholieke Universiteit (KU) Leuven Special Research Fund (BOF) (C14/19/096 and C14/23/121), Research Foundation - Flanders (G072921N) and NIH award R01HL161365. K.D.W. was supported by the Belgian American Education Foundation and NIH award R01HL161365. A.M. was supported by NIH award R01HL161365. D.G., and E.T. were supported by NIH awards R01HL161365 and R03HD111492 and E.T. was further supported by the Lowy Foundation USA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants of the 100,000 Genomes Project, the 100,000 Genomes Project Pilot Project and the Genomic Medicine Service were enrolled to the National Genomic Research Library (NGRL) under a protocol approved by the East of England-Cambridge Central Research Ethics Committee (ref: 20/EE/0035). We obtained written informed consent to publish additional clinical data from a subset of the affected cases in the NGRL following local best practices. NIHR BioResource participants were enrolled under a protocol approved by the East of England Cambridge South Research Ethics Committee (ref. 13/EE/0325).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint authors.
Data availability
Genetic and phenotypic data for the 100KGP study participants, the 100KGP Pilot study participants and the GMS participants are available through the Genomics England Research Environment via the application at https://www.genomicsengland.co.uk/join-a-gecip-domain. Data pertaining to: WGS data were obtained for 78,132 100KGP participants, 4,054 100KGP Pilot participants, 32,030 GMS participants (v3) and 13,037 NBR participants; HPO phenotype data from the ‘rare_diseases_participant_phenotype’ table (Main Programme v14), ‘observation’ table (GMS v3) and ‘hpo’ table (Rare Diseases Pilot v3); Specific Disease class data from the ‘rare_diseases_participant_disease’ table (Main Programme v13); ICD10 codes from the ‘hes_apc’ table (Main Programme v13); pedigree information from the ‘rare_diseases_pedigree_member’ table (Main Programme v13), ‘referral_participant’ table (GMS v3), and ‘pedigree’ table (Rare Diseases Pilot v3); explained/unexplained status of cases from the ‘gmc_exit_questionnaire’ tables (Main Programme v18, GMS v3). Accession codes for NBR data are given in ref.19. CADD v.1.5 (https://cadd.gs.washington.edu/), gnomAD v.3.0 (https://gnomad.broadinstitute.org/) and Ensembl v.104 (http://may2021.archive.ensembl.org/index.html) were used for variant annotation. Expression data for U2 snRNA homologs were extracted from the file ‘GTEx_Analysis_2017-06-05_v8_RSEMv1.3.0_transcript_expected_count.gct.gz’ available from the GTEx Portal. Data presented in this paper were requested from the Genomics England Airlock on August 13, 2024 at 3:39am British Summer Time (BST). The manuscript was submitted to the Genomics England Publication Committee on August 21, 2024 at 23:51 BST and approved for submission on August 27, 2024 at 15:52 BST.
